Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$8.11 +0.2%	$8.54	$6.51 ▼ $13.27	$8.57M	1.63	1,443 shs	492 shs
CPMD Golden Dragon	$0.00 -21.9%	$0.00	$0.00 ▼ $0.01	$2.11M	2.12	142,628 shs	33,720 shs
MTNB Matinas Biopharma	$1.70 -0.6%	$1.05	$0.47 ▼ $6.55	$8.65M	1.32	452,396 shs	661,059 shs
TRAW Traws Pharma	$1.34 -5.6%	$1.56	$0.97 ▼ $19.44	$10.03M	1.14	152,159 shs	145,617 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	+0.31%	+1.39%	+7.49%	-1.45%	+4.85%
CPMD Golden Dragon	-21.88%	-21.88%	-16.67%	-54.55%	-76.19%
MTNB Matinas Biopharma	-0.58%	+14.86%	+77.08%	+120.78%	+815.46%
TRAW Traws Pharma	-5.63%	-17.79%	-16.25%	+11.67%	+133,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.5923 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	0.6
CPMD Golden Dragon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	1.5385 of 5 stars	0.0	5.0	0.0	0.0	3.9	0.0	0.6
TRAW Traws Pharma	1.6054 of 5 stars	0.0	5.0	0.0	0.0	2.0	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	270.14% Upside
CPMD Golden Dragon	0.00	N/A	N/A	N/A
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A
TRAW Traws Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$170.62K	50.35	N/A	N/A	$10.37 per share	0.78
CPMD Golden Dragon	$820K	2.01	N/A	N/A	($0.04) per share	-0.06
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A
TRAW Traws Pharma	$230K	41.13	N/A	N/A	$1.17 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	3,584.49%	-54.27%	-49.15%	9/1/2025 (Estimated)
CPMD Golden Dragon	-$9.91M	-$0.01	N/A	∞	N/A	-423.36%	N/A	-34.17%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A
TRAW Traws Pharma	-$166.52M	$88.83	0.02	N/A	N/A	3,028.25%	-1,812.48%	512.72%	N/A

Latest CPMD, ADXN, TRAW, and MTNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	TRAW Traws Pharma	-$8.75	-$0.11	+$8.64	-$0.11	$0.06 million	$2.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
CPMD Golden Dragon	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	3.02	3.02
CPMD Golden Dragon	N/A	0.05	0.01
MTNB Matinas Biopharma	N/A	5.53	5.53
TRAW Traws Pharma	N/A	1.81	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
CPMD Golden Dragon	N/A
MTNB Matinas Biopharma	11.77%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
CPMD Golden Dragon	1.27%
MTNB Matinas Biopharma	4.60%
TRAW Traws Pharma	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
CPMD Golden Dragon	4	660.63 million	652.24 million	Not Optionable
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A
TRAW Traws Pharma	17	7.06 million	6.10 million	Optionable

CPMD, ADXN, TRAW, and MTNB Headlines

Recent News About These Companies

Traws Pharma receives approval to proceed with Phase 2 COVID studies

August 18 at 12:07 PM | msn.com

Traws Pharma, Inc.: Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

August 18 at 12:07 PM | finanznachrichten.de

Traws Pharma Gains Approval for Phase 2 COVID-19 Trials

August 18 at 12:07 PM | msn.com

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

August 18 at 7:00 AM | globenewswire.com

Traws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral Programs

August 16, 2025 | msn.com

Traws Pharma Advances Antiviral Programs Amid Revenue Growth

August 16, 2025 | theglobeandmail.com

Traws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call Transcript

August 15, 2025 | insidermonkey.com

Traws Pharma, Inc.: Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

August 14, 2025 | finanznachrichten.de

Traws Pharma Stock Short Interest Report | NASDAQ:TRAW - Benzinga

August 14, 2025 | benzinga.com

Traws Pharma Posts Q2 Revenue Jump

August 14, 2025 | aol.comA

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

August 14, 2025 | msn.com

Traws Pharma Reports Q2 2025 Financial Results

August 14, 2025 | msn.com

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

August 14, 2025 | finance.yahoo.com

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

August 14, 2025 | seekingalpha.com

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

August 14, 2025 | globenewswire.com

Traws Pharma to Announce Q2 Results and Business Update on August 14

August 10, 2025 | msn.com

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

August 8, 2025 | globenewswire.com

TRAW - Traws Pharma Inc Sustainability - Morningstar

July 16, 2025 | morningstar.comM

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

July 8, 2025 | msn.com

Traws Pharma announces chief financial officer transition

July 5, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPMD, ADXN, TRAW, and MTNB Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$8.10 +0.02 (+0.19%)

Closing price 08/19/2025 02:56 PM Eastern

Extended Trading

$8.10 0.00 (0.00%)

As of 08/19/2025 04:04 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Golden Dragon OTCMKTS:CPMD

$0.0025 0.00 (-21.88%)

As of 08/19/2025 03:44 PM Eastern

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

Matinas Biopharma NYSE:MTNB

$1.70 -0.01 (-0.58%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$1.70 0.00 (-0.29%)

As of 08/19/2025 07:59 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Traws Pharma NASDAQ:TRAW

$1.34 -0.08 (-5.63%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.04 (+3.36%)

As of 08/19/2025 07:45 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time